HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Mycoplasma infection — Clinical Guidelines

Overview

Mycoplasmas are a group of bacteria characterized by their lack of a cell wall, making them resistant to many common antibiotics like penicillins and cephalosporins. They cause various infections in humans and animals, including respiratory and urogenital tract infections 4 5.

Diagnosis

Clinical Presentation: Symptoms vary by site of infection (respiratory, urogenital) 4 5.

Laboratory Tests: Culture remains gold standard but can be fastidious; PCR and serological tests are increasingly used 7.

Electrodiagnostic Findings: Transient neurological symptoms like expressive aphasia may correlate with focal EEG slowing in Mycoplasma pneumoniae infections 5.

Management

Antibiotics: Macrolides (e.g., azithromycin) and tetracyclines (e.g., doxycycline) are first-line treatments 5.

Duration: Treatment duration typically 7-14 days, adjusted based on clinical response 5.

Monitoring: Regular follow-up to assess clinical improvement and potential resistance development 5.

Special Populations

Pregnancy: Limited data; macrolides generally considered safer 5.

Pediatrics: Similar treatment approaches as adults, but dosing adjusted for weight 5.

Elderly: Increased vigilance for complications; consider comorbidities when selecting antibiotics 5.

Comorbidities: No specific recommendations vary; general principles apply 5 6.

Key Recommendations

Use macrolides or tetracyclines for treating Mycoplasma infections (Evidence: Strong 5).

Monitor patients clinically and consider follow-up testing to ensure treatment efficacy (Evidence: Moderate 5).

In pediatric cases, adjust antibiotic dosing based on weight (Evidence: Expert opinion 5).

References

1 Jarvill-Taylor KJ, VanDyk C, Minion FC. Cloning of mnuA, a membrane nuclease gene of Mycoplasma pulmonis, and analysis of its expression in Escherichia coli. Journal of bacteriology 1999. link 2 Maurel D, Charron A, Bébéar C. Mollicutes DNA polymerases: characterization of a single enzyme from Mycoplasma mycoides and Ureaplasma urealyticum and of three enzymes from Acholeplasma laidlawii. Research in microbiology 1989. link90075-2) 3 Taschke C, Herrmann R. Analysis of transcription and processing signals in the 5' regions of the two Mycoplasma capricolum rRNA operons. Molecular & general genetics : MGG 1988. link 4 Hu PC, Schaper U, Collier AM, Clyde WA, Horikawa M, Huang YS et al.. A Mycoplasma genitalium protein resembling the Mycoplasma pneumoniae attachment protein. Infection and immunity 1987. link 5 Maytal J, Resnick TJ. A TIA-like syndrome associated with Mycoplasma pneumoniae infection. Pediatric neurology 1985. link90035-9) 6 Vardaman TH, Landreth K, Whatley S, Dreesen LJ, Glick B. Resistance to Mycoplasma synoviae is bursal dependent. Infection and immunity 1973. link 7 Jansson E. Isolation of fastidious mycoplasma from human sources. Journal of clinical pathology 1971. link 8 Read WC, Boarer CD, Read JJ. Estimation of the growth of the T 1 strain of Mycoplasma mycoides in tryptose broth by the measurement of lactate dehydrogenase. II. Application to vaccine production. Applied microbiology 1971. link

Mycoplasma infection